NCT04713176 is a Phase 3 clinical trial of DWJ1248 with Remdesivir in Severe COVID-19, sponsored by Daewoong Pharmaceutical Co. LTD..

Who is sponsoring NCT04713176?

NCT04713176 is sponsored by Daewoong Pharmaceutical Co. LTD..

What drugs are being tested in NCT04713176?

Interventions in NCT04713176: DWJ1248 with Remdesivir, Placebo with Remdesivir.

What condition does NCT04713176 study?

NCT04713176 studies Severe COVID-19.

Is NCT04713176 still recruiting?

NCT04713176 is currently terminated. Last updated 29 September 2023.

Last reviewed 2023-09-29 · How we verify

NCT04713176

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients

Terminated Phase 3 Last updated 29 September 2023

What this trial tests

Phase 3 trial testing DWJ1248 with Remdesivir in Severe COVID-19 in 240 participants. Terminated before completion.

Timeline

2 February 2021

Primary endpoint
2 May 2022

9 December 2022

Quick facts

Lead sponsor	Daewoong Pharmaceutical Co. LTD.
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	240
Start date	2 February 2021
Primary completion	2 May 2022
Estimated completion	9 December 2022
Sites	1 location across South Korea

Drugs / interventions tested

DWJ1248 with Remdesivir — full drug profile →
Placebo with Remdesivir — full drug profile →

Conditions studied

Severe COVID-19 — all drugs for Severe COVID-19 →

Sponsor

Daewoong Pharmaceutical Co. LTD. — full company profile →

Who can join

19 and older, any sex, with Severe COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Efficacy and Safety of DWJ1248 with Remdesivir in Severe COVID-19 Patients

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Remdesivir for the treatment of COVID-19.
Ansems K, Grundeis F, Dahms K, Mikolajewska A, et al · · 2021 · cited 89× · PMID 34350582 · DOI 10.1002/14651858.cd014962
Small molecules in the treatment of COVID-19.
Lei S, Chen X, Wu J, Duan X, et al · · 2022 · cited 74× · PMID 36464706 · DOI 10.1038/s41392-022-01249-8
Remdesivir for the treatment of COVID-19.
Grundeis F, Ansems K, Dahms K, Thieme V, et al · · 2023 · cited 55× · PMID 36695483 · DOI 10.1002/14651858.cd014962.pub2
The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment.
Wettstein L, Kirchhoff F, Münch J. · · 2022 · cited 55× · PMID 35163273 · DOI 10.3390/ijms23031351
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses.
White JM, Schiffer JT, Bender Ignacio RA, Xu S, et al · · 2021 · cited 53× · PMID 34933447 · DOI 10.1128/mbio.03347-21
Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
Negru PA, Radu AF, Vesa CM, Behl T, et al · · 2022 · cited 18× · PMID 35131656 · DOI 10.1016/j.biopha.2022.112700
The discovery and development of transmembrane serine protease 2 (TMPRSS2) inhibitors as candidate drugs for the treatment of COVID-19.
Mantzourani C, Vasilakaki S, Gerogianni VE, Kokotos G. · · 2022 · cited 18× · PMID 35072549 · DOI 10.1080/17460441.2022.2029843

Verify or expand the search:

Other recruiting trials for Severe COVID-19

Currently open trials in the same condition.

NCT05233605 — Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation · recruiting

Other Daewoong Pharmaceutical Co. LTD. trials

Trials by the same sponsor.

NCT07515560 — Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study · not yet recruiting
NCT07516977 — Noseguard for Prevention of Respiratory Infections in Real-World Use · NA · not yet recruiting
NCT07539415 — A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Hea · Phase 1 · not yet recruiting
NCT07267221 — Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers · Phase 1 · recruiting
NCT07256600 — PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04713176 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daewoong Pharmaceutical Co. LTD.
Last refreshed: 29 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04713176.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing